

## **Aytu BioPharma to Participate in the Sidoti Micro-Cap Virtual Conference on August 14-15, 2024**

**DENVER, CO / August 8, 2024** / Aytu BioPharma, Inc. (the “Company” or “Aytu”) (Nasdaq: AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, Chief Executive Officer, will participate in a webcasted presentation and host one-on-one meetings with investors at the Sidoti Micro-Cap Virtual Conference, taking place virtually on Wednesday, August 14, 2024, and Thursday, August 15, 2024.

### **Webcast**

The webcasted fireside chat will take place at 12:15 p.m. Eastern time on Thursday, August 15, 2024. The webcast can be accessed by visiting the investor relations section of the Company’s website at <https://investors.aytubio.com> or directly here. The webcast will also be available for replay following the event.

### **1×1 Meetings**

Management will also be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact your Sidoti representative or the Company’s investor relations team at [aytu@lythampartners.com](mailto:aytu@lythampartners.com).

### **About Aytu BioPharma, Inc.**

Aytu is a pharmaceutical company focused on commercializing novel therapeutics. The Company’s prescription products include Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), Karbinal® ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. To learn more, please visit [aytubio.com](http://aytubio.com).

### **Contacts for Investors**

Mark Oki, Chief Financial Officer  
Aytu BioPharma, Inc.  
[moki@aytubio.com](mailto:moki@aytubio.com)

Robert Blum or Roger Weiss  
Lytham Partners  
[aytu@lythampartners.com](mailto:aytu@lythampartners.com)

**SOURCE:** Aytu BioPharma, Inc.

View the original press release on [accesswire.com](https://www.accesswire.com)